Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06759558 · ClinicalTrials.gov registry record · Phase 2
Allopregnanolone (Zuranolone) in Post-stroke Depression
A Phase 2 study of Post Stroke Depression, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06759558 is a Phase 2 study of Post Stroke Depression that is actively recruiting participants, run by Duke University. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06759558, a Phase 2 study of Post Stroke Depression, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are: * Is zuranolone safe to take by participants who have moderate to severe post-stroke depression? * Is zuranolone well-tolerated by participants who have moderate to severe post-stroke depression? * Does zuranolone treat moderate to severe post-stroke depression? The study will enroll six participants. All participants will be given 50 mg of zuranolone for 14 days. Participants will be asked to provide blood samples, complete some questionnaires including those related to mood and a cognitive assessment.
Conditions Studied
Interventions
- DRUG Zuranolone
Study Locations (1)
North Carolina
- Duke South Neurology Clinic 1L - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06759558
The ClinicalTrials.gov registry entry for NCT06759558 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Stroke Depression appearing as the primary indexed condition, and to 1 intervention - of which Zuranolone is the first listed.
NCT06759558 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06759558 about?
NCT06759558 is a clinical study titled "Allopregnanolone (Zuranolone) in Post-stroke Depression". The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it w...
What is the current status of trial NCT06759558?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2026-01-14. Estimated completion is 2026-06-30.
What conditions does trial NCT06759558 study?
This clinical trial studies the following conditions: Post Stroke Depression.
What interventions are being tested in trial NCT06759558?
The interventions under investigation include: Zuranolone (DRUG).
Who is sponsoring clinical trial NCT06759558?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06759558 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Stroke Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.